StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MCGS.QA$5.84-1.53%
Fair $5.84+0.0%

MCGS.QA

Medicare Group Q.P.S.C.

Healthcare / Medical Care FacilitiesQatar

$5.84

-0.09 (-1.53%)

Fairly Valued+0.0%Fair Value $5.84Fund rank 35/100 · Data gapFallback financials|
SA 53/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $35.1M · quality 73.7/100

Data gap 35/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 66/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

53/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · MCGS.QALocal privado en este navegador · Medicare Group Q.P.S.C.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.6B

P/E

25.4x

↑

EV/EBITDA

19.1x

↑

ROE

7.4%

↑

Gross Margin

35.1%

↓

Debt/Equity

0.15

↓
52-Week Range$6
$5$7

TradingView lightweight chart

MCGS.QA price, volumen y niveles de valoración

Último $5.839Periodo +548.8%
Fair value: $5.839

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+1.0%

FCF CAGR

-15.2%

FCF margin

7.0%

FCF / Net income

0.46x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $502.6M · net income $76.0M · FCF $35.1M

2022-FY → 2025-FY

Gross margin

35.1%-3.0% pts

Operating margin

12.7%-2.6% pts

Net margin

15.1%-1.1% pts

FCF margin

7.0%-4.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$502.6M$502.6M$523.5M$486.0M$487.2M
Net Income$76.0M$76.0M$60.1M$65.7M$79.2M
EBITDA$90.3M$90.3M$110.4M$97.3M$109.7M
EPS0.270.270.210.230.28
Gross Margin35.1%35.1%37.6%36.2%38.1%
Operating Margin12.7%12.7%16.0%14.2%15.4%
Net Margin15.1%15.1%11.5%13.5%16.3%
Balance Sheet
Debt/Equity0.150.150.180.130.12
Current Ratio1.341.34———
Cash Flow
Free Cash Flow$35.1M$35.1M$54.2M$24.0M$57.7M
Returns
ROE7.4%7.4%6.0%6.5%7.6%
Valuation
P/E25.3925.3920.7023.8322.52
EV/EBITDA19.1419.1411.9317.0716.90
P/B1.591.591.231.521.71
Growth & Yield
Revenue Growth-4.0%-4.0%7.7%-0.2%—
EPS Growth26.8%26.8%-7.4%-17.9%—
Dividend Yield3.7%3.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

24.3%

exigente

EPS terminal req.

$0.52

Spread vs growth

2.5%

5Y implied EPS CAGR

18.4%

exigente

EPS terminal req.

$0.63

Spread vs growth

8.4%

10Y implied EPS CAGR

14.1%

razonable

EPS terminal req.

$1.01

Spread vs growth

12.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +20.7%

Total return

+20.7%

Start / end P/E

23.4x → 21.6x

EPS bridge

0.21 → 0.27

Residual

-2.1%

EPS growth+26.8%
Multiple rerating-7.7%
Dividend+3.7%
Residual / FX / buybacks / cross-term-2.1%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.